Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 8/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 8/20 | 0.39 |
| ▸ | MLNR | O43193 | 8/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29613576 | 0.99 | XIAP (0.39) | XIAPBIRC2MLNRCHRM3HRH4 | |
| Hydrochloric Acid SCHEMBL21354281 | 0.99 | XIAP (0.39) | XIAPBIRC2MLNRCHRM3HRH4 | |
| SCHEMBL19785978 | 0.86 | BIRC2 (0.38) | XIAPBIRC2MLNRCHRM3PDE10A | |
| Hydrochloric Acid SCHEMBL21354312 | 0.85 | BIRC2 (0.37) | XIAPBIRC2MLNRCHRM3PDE10A | |
| SCHEMBL22383760 | 0.82 | LMNA (0.45) | CHRM3 | |
| SCHEMBL19785897 | 0.81 | MLNR (0.35) | XIAPBIRC2MLNRCHRM3PDE10A | |
| Hydrochloric Acid SCHEMBL21354336 | 0.80 | MLNR (0.34) | XIAPBIRC2MLNRCHRM3PDE10A | |
| Hydrochloric Acid SCHEMBL29613563 | 0.80 | MLNR (0.34) | XIAPBIRC2MLNRCHRM3PDE10A | |
| SCHEMBL17294318 | 0.79 | MEN1 (0.43) | XIAPBIRC2MLNR | |
| SCHEMBL17298254 | 0.79 | MEN1 (0.43) | XIAPBIRC2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
| CN-107001342-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RORA, NR1H3 | XIAP 4531/4885BIRC2 4008/4885MLNR 996/4885 |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | XIAP 4037/4885BIRC2 3917/4885MLNR 631/4885 |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | XIAP 4037/4885BIRC2 3917/4885MLNR 631/4885 |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RXRG, RXRB | XIAP 4037/4885BIRC2 3917/4885MLNR 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.